# ORIENT-32 (NCT03794440)

> A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.

No report yet. It can be ordered.

- Drugs tested: sintilimab plus IBI305
- Indication: first-line unresectable hepatocellular carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03794440
- Phase: PHASE2, PHASE3
- Status: UNKNOWN
- Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
- Conditions: Hepatocellular Carcinoma
- Interventions: Sintilimab; IBI305; Sorafenib
- Enrollment: 595
- Primary outcome: Overall survival (OS)
- Primary outcome: Progression-free survival (PFS)

## Indexed commentary on ORIENT-32 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 podcast episodes
- 3 posts on X
- 1 YouTube video

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=orient-32-nct03794440
